Cryofocus Medtech (Shanghai) Co (HKSE:06922) Cash-to-Debt : 15.85 (As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Cryofocus Medtech (Shanghai) Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cryofocus Medtech (Shanghai) Co's cash to debt ratio for the quarter that ended in Jun. 2023 was 15.85.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cryofocus Medtech (Shanghai) Co could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Cryofocus Medtech (Shanghai) Co's Cash-to-Debt or its related term are showing as below:

HKSE:06922' s Cash-to-Debt Range Over the Past 10 Years
Min: 9.39 Med: 18.73 Max: 57.21
Current: 9.39

During the past 4 years, Cryofocus Medtech (Shanghai) Co's highest Cash to Debt Ratio was 57.21. The lowest was 9.39. And the median was 18.73.

HKSE:06922's Cash-to-Debt is ranked better than
72.1% of 828 companies
in the Medical Devices & Instruments industry
Industry Median: 1.97 vs HKSE:06922: 9.39

Cryofocus Medtech (Shanghai) Co Cash-to-Debt Historical Data

The historical data trend for Cryofocus Medtech (Shanghai) Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cryofocus Medtech (Shanghai) Co Cash-to-Debt Chart

Cryofocus Medtech (Shanghai) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

57.21

17.54

19.91

9.39

Cryofocus Medtech (Shanghai) Co Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial			17.54	N/A	19.91	15.85	9.39

Competitive Comparison of Cryofocus Medtech (Shanghai) Co's Cash-to-Debt

For the Medical Devices subindustry, Cryofocus Medtech (Shanghai) Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cryofocus Medtech (Shanghai) Co's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cryofocus Medtech (Shanghai) Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cryofocus Medtech (Shanghai) Co's Cash-to-Debt falls into.

Cryofocus Medtech (Shanghai) Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cryofocus Medtech (Shanghai) Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	252.849	/	(3.833	+	8.866)
	=	19.91

Cryofocus Medtech (Shanghai) Co's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	173.926	/	(3.022	+	7.952)
	=	15.85

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Cryofocus Medtech (Shanghai) Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cryofocus Medtech (Shanghai) Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cryofocus Medtech (Shanghai) Co Ltd (HKSE:06922) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Building 15, Lane 3399, Kangxin Road, Pudong New Area, Shanghai, CHN, 200120

Website

https://www.cryofocus.com

Cryofocus Medtech (Shanghai) Co Ltd is a medical device company engaged in the research and development, manufacture and sale of cryoablation minimally-invasive interventional treatment technology and related medical products. It has two Core Products, the Bladder Cryoablation System and the Endoscopic Clip for Anastomosis. The Bladder Cryoablation System is a cryotherapy device designed for the treatment of bladder cancer. The Endoscopic Clip for Anastomosis is an anastomotic device for the closure of soft tissue in the digestive tract, which is one of the over-the-scope clips. Geographically company's key revenue is generated from China.

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Headlines

No Headlines